Alexopoulou Alexandra, Vasilieva Larisa, Mani Iliana, Agiasotelli Danai, Pantelidaki Helen, Dourakis Spyros P
a 2nd Department of Medicine , Medical School, National and Kapodistrian University of Athens, Hippokration General Hospital , Athens , Greece.
Scand J Gastroenterol. 2017 Dec;52(12):1385-1390. doi: 10.1080/00365521.2017.1369560. Epub 2017 Aug 29.
Acute decompensation (AD) of cirrhosis is characterized by high mortality. We aimed to validate the performance in predicting mortality of both the chronic-liver-failure-consortium (CLIF-C) acute-on-chronic liver failure (ACLF) and CLIF-C AD scores in a cohort of patients admitted for AD.
In this prospective cohort study, patients were followed-up during their hospital stay and for 365 days thereafter.
About 182 patients with AD were enrolled including 78 (42.8%) who met the criteria for ACLF (ACLF-group) while the remaining had AD without ACLF (AD-group). 56.4% and 56.7% of the ACLF- and AD-groups, respectively, had alcoholic cirrhosis and 85.9% of the ACLF-group hepatic encephalopathy. Only few patients were hospitalized in the intensive care unit (ICU) or transplanted. The probabilities of death estimated for both scores were similar to the overall mortality rates observed at all time points. The model had a good fit in the AD-group at 90 days (p = .974) but a worse, yet adequate, in the ACLF-group at 28 days (p = .08). The CLIF-C ACLF or AD scores had an adequate, predictive discrimination ability for mortality at all time points, with Harrel's concordance index-C ranging between 0.64 and 0.65 or 0.64 and 0.68, respectively. Both scores showed a similar predictive accuracy for mortality compared to those of MELD, MELD-Na and Child-Pugh.
In this population without access to appropriate ICU treatment, the CLIF-C ACLF and AD performed worse than in studies with patients having ICU access. In addition, the CLIF scores were not superior to classical ones in this setting.
肝硬化急性失代偿(AD)的特点是死亡率高。我们旨在验证慢性肝衰竭联盟(CLIF-C)慢加急性肝衰竭(ACLF)和CLIF-C AD评分在一组因AD入院患者中预测死亡率的性能。
在这项前瞻性队列研究中,对患者在住院期间及之后365天进行随访。
纳入了约182例AD患者,其中78例(42.8%)符合ACLF标准(ACLF组),其余患者为无ACLF的AD(AD组)。ACLF组和AD组分别有56.4%和56.7%的患者患有酒精性肝硬化,ACLF组有85.9%的患者患有肝性脑病。只有少数患者入住重症监护病房(ICU)或接受移植。两个评分估计的死亡概率与所有时间点观察到的总体死亡率相似。该模型在AD组90天时拟合良好(p = 0.974),但在ACLF组28天时拟合较差但仍可接受(p = 0.08)。CLIF-C ACLF或AD评分在所有时间点对死亡率均具有足够的预测鉴别能力,Harrel一致性指数-C分别在0.64至0.65或0.64至0.68之间。与终末期肝病模型(MELD)、MELD-Na和Child-Pugh评分相比,这两个评分对死亡率的预测准确性相似。
在这个无法获得适当ICU治疗的人群中,CLIF-C ACLF和AD评分的表现比在有ICU治疗的患者的研究中更差。此外,在这种情况下,CLIF评分并不优于经典评分。